Member Info for Professor1

Roger65

That is 5% royalties on 12B annual sales by any large pharma

@Marty130

More like 600 million per anum

GLA

Hi Bobsponge

Sure, I have simply taken the total cashflow of $12.5 B you had in your post and instead of dividing this by the total number of shares, what you need to do is divide this by 20 years first as the cashflows ate assumed to accrue over that time period. Then for each year, we need to PV. So, the cashflows in year 1, assuming at the end of the year, needs to be PVd by 1 assuming a certain discount factor based on the risk. The higher the rusk, the higher the discount rate used, I used a higher rate of 10%. You do this for year 2 cashflows and so on. I have then assumed 25% tax rate. Finally, add the PVs of all the years less tax. Hope this fine.

GLA

OTM

Based on those simplistic data ,yes.

GLA

The PV of these cash flows over 20 years work out to be $5B or say £4B less tax @ say 25% gives you £3B. /500m shares roughly £6/ share

Sorry OTM!

GLA

Sharia Banking will be massive and the co is positioning for this

GLA

Maybe he/she is at the conference with a listening device

GLA

Im holding for a bigger prize in a few weeks time

GLA

Just topped up

GLA

Now starting to appear which I would thow it in the bin.

Instead, I would listen to what the management has been and will say.

GLA

@AICommand

Sure, will do

GLA

@AICommand ,nice one

GLA

Bought 1147584 to start with

GLA

@StMartins

Came across this co, and I like the investment - Alludium. I will be investing here

@rebarm

You are right, all efforts currently on P140. However, when it comes to deals, Tim has spoken about " other products that are not talked about a lot" Tim's phrase " One or more deals"

"Metabolism | BioGlucagon' (new program)

ImmuPharma announced on 30 March 2020 that it has developed a new product, BioGlucagon, as a potential new rescue therapy for low sugar events in diabetes. Existing glucagon products have poor solubility and are inconvenient with variable dosing due to poor solubility creating risks for patients. BioGlucagon has 100% solubility, can be formulated in pre-filled syringe pens and could be used in insulin pumps. The next step will be to progress towards a bio equivalence study for BioGlucagon, which if successful could result with a potential market launch date in 2022. Partnering discussions will now progress in parallel."

Wonder when Tim talks about other products which IMM don't discuss a lot, this is one of them, a very significant market

GLA

OTM

This was my understanding of the 2019 Agreement which I posted some while ago, copied below:

(A) the original Agreement with Avion for jointly developing Lupus AND

(B) the new P140 Patent which includes, EXTREMELY IMPORTANTLY, the Diagnostic patent that was recently filed

THE ABOVE CREATES A DISTINCT TWO TIER STRUCTURE, IN MY VIEW, FOR THE US MARKET, BETWEEN THE ESTABLISHED DRUG RIGHTS AND THE NEW DIAGNOSTIC INTELLECTUAL PROPERTY (IP). I believe because of the complexities involved, we have not heard Tim mention a word about the US.

Taking the above (A) and (B) in a bit more detail, what we have is:

(A) US THERAPEUTIC RIGHTS (LUPUS + OTHER INDICATIONS)

(I) LUPUS - Under the 2019 Agreement, Avion has the right to exploit P140 for the development of LUPUS.

(ii) The Agreement has a "Future Indications" Clause under which Avion is allowed to "explore" other indications in the US 'UNDER THE EXISTING P140 THERAPEUTIC IP'.

PLEASE TAKE NOTE THAT THE AGREEMENT DOES NOT STATE FUTURE INDICATIONS UNDER ANY FUTURE IP

(B) THE NEW PATENT FILED IN SEPTEMBER 2025

This introduces a new diagnostic test to identify "Type M Responders". THIS WAS NOT PART OF THE ORIGINAL 2019 AGREEMENT.

1) I believe that because the Diagnostics is a NEW IP distinct from the original therapeutic patent, Avion DOES NOT automatically have the rights to this test and does not automatically own

But, there is no doubt in my mind that some sort of re- negotiation is in the making with Avion.

OTM

So, under scenario (2), I envisage IMM and Avion running under 2 joint Agreements at the same time

OTM

1) FOR LUPUS

What you will have is :

(A) Payments to IMM under the old 2019 Agreement AND

EITHER

(1) An addendum to the 2019 Agreement to cater for the massive fees for the use of the Diagnostics

OR

(2) A separate new Agreement to cater for the Diagnostics and the payment arrangements thereunder

For Lupus, there is no escaping for Avion to pay up additional fees.

G L A